newsfilter
← Latest News
GlobeNewswire·

Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Successfully transitioned SIL204 from regulatory preparation into an active Phase 2/3 clinical program in locally advanced pancreatic cancer, with trial initiation at Tel Aviv Sourasky Medical Center in July 2026